New Anticomplement Drugs in Nephrology: Mechanism and Indication

Area of Science:

• Immunology
• Nephrology
• Pharmacology

Background:

• The complement system is crucial for innate immunity but its dysregulation drives kidney diseases.
• Overactivated complement pathways contribute to atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G), and other nephropathies.
• Uncontrolled complement activation leads to renal inflammation, microvascular injury, and fibrosis.

Purpose of the Study:

• To review the mechanisms, clinical indications, and evidence for targeted anticomplement therapies in kidney diseases.
• To discuss challenges and future directions in the use of these novel treatments.
• To highlight the potential of personalized, biomarker-driven approaches.

Main Methods:

• Review of recent advances in complement biology and therapeutic development.
• Analysis of clinical trial data and real-world experience with anticomplement drugs.
• Discussion of safety, cost, and treatment optimization strategies.

Main Results:

• Development of targeted therapies including C5, C3, factor B/D, C5a receptor, and MASP-2 inhibitors.
• Evidence from clinical trials supports the efficacy of these agents in various kidney diseases.
• Ongoing research focuses on optimizing treatment and exploring personalized approaches.

Conclusions:

• Anticomplement therapies represent a significant advancement in nephrology for complement-mediated kidney diseases.
• These targeted interventions can improve patient outcomes by reducing disease progression and organ damage.
• Personalized treatment strategies hold promise for managing complement-driven renal disorders effectively.